Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: August 13, 2022

Details for Patent: 8,301,238

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,301,238 protect, and when does it expire?

Patent 8,301,238 protects IONSYS and is included in one NDA.

This patent has eighty-eight patent family members in eighteen countries.

Summary for Patent: 8,301,238
Title:Two-part electrotransport device
Abstract: A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
Inventor(s): Netzel; Zita S. (Los Altos, CA), Lemke; John (Pleasanton, CA), Seward; David (Seattle, WA), Read; Brian W. (Brier, WA), White; Bradley E. (Mason, OH), Chen; Corinna X. (Oakland, CA), Hayter; Paul (Mountain View, CA)
Assignee: Incline Therapeutics, Inc. (Redwood City, CA) Alza Corporation (Vacaville, CA)
Application Number:13/250,031
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 8,301,238

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
The Medicines Co IONSYS fentanyl hydrochloride SYSTEM;IONTOPHORESIS, TRANSDERMAL 021338-001 May 22, 2006 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,301,238

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012238095 See Plans and Pricing
Australia 2012238096 See Plans and Pricing
Australia 2013266914 See Plans and Pricing
Australia 2013274873 See Plans and Pricing
Australia 2015271708 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.